Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$25.50 USD
+0.02 (0.08%)
Updated May 23, 2024 04:00 PM ET
After-Market: $25.52 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Deciphera Pharmaceuticals, Inc. [DCPH]
Reports for Purchase
Showing records 61 - 80 ( 98 total )
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Look Towards Future Value, as Qinlocks 2L GIST Hope Dies; Reit Buy and Lowering Our PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INTRIGUE Readout in 4Q21 Remains Central Focus; Reit Buy and $70PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ESMO Updates from Rebastinib and Vimseltinib Highlight Value Outside of Qinlock
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Steady Qinlock Sales Look to be Accelerated by 2L Boost
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Sentiment Surrounds INTRIGUE Despite Moderate 4L Expectations; Reit Buy and Lowering our PT to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department